"Benzamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
BENZOIC ACID amides.
Descriptor ID |
D001549
|
MeSH Number(s) |
D02.065.277 D02.241.223.100.100 D02.455.426.559.389.127.085
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzamides".
Below are MeSH descriptors whose meaning is more specific than "Benzamides".
This graph shows the total number of publications written about "Benzamides" by people in this website by year, and whether "Benzamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1995 | 2 | 0 | 2 |
1998 | 0 | 2 | 2 |
2000 | 0 | 2 | 2 |
2001 | 0 | 7 | 7 |
2002 | 0 | 23 | 23 |
2003 | 1 | 48 | 49 |
2004 | 1 | 47 | 48 |
2005 | 0 | 34 | 34 |
2006 | 3 | 50 | 53 |
2007 | 3 | 73 | 76 |
2008 | 1 | 62 | 63 |
2009 | 3 | 62 | 65 |
2010 | 4 | 67 | 71 |
2011 | 11 | 44 | 55 |
2012 | 12 | 43 | 55 |
2013 | 25 | 15 | 40 |
2014 | 15 | 17 | 32 |
2015 | 7 | 6 | 13 |
2016 | 6 | 6 | 12 |
2017 | 10 | 12 | 22 |
2018 | 4 | 7 | 11 |
2019 | 5 | 15 | 20 |
2020 | 10 | 5 | 15 |
2021 | 8 | 12 | 20 |
2022 | 1 | 11 | 12 |
2023 | 1 | 3 | 4 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzamides" by people in Profiles.
-
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib. Haematologica. 2024 Feb 01; 109(2):676-681.
-
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363.
-
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 Feb; 24(2):105-121.
-
Intravenous tecovirimat treatment of oral monkeypox lesions in a patient with HIV-1. J Med Virol. 2023 09; 95(9):e29078.
-
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies. Cancer Med. 2023 05; 12(9):10612-10624.
-
Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center. Leuk Lymphoma. 2023 05; 64(5):1050-1053.
-
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022 10 03; 24(10):1776-1789.
-
HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression. J Zhejiang Univ Sci B. 2022 Aug 15; 23(8):666-681.
-
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia. 2022 09; 36(9):2261-2268.
-
Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors. J Biol Chem. 2022 08; 298(8):102226.